Free Trial
NASDAQ:ORMP

Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

Oramed Pharmaceuticals logo
$2.20 0.00 (0.00%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$2.18 -0.02 (-0.91%)
As of 08/29/2025 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Oramed Pharmaceuticals Stock (NASDAQ:ORMP)

Key Stats

Today's Range
$2.16
$2.21
50-Day Range
$2.06
$2.30
52-Week Range
$1.82
$3.09
Volume
83,455 shs
Average Volume
73,015 shs
Market Capitalization
$90.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Oramed Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
18th Percentile Overall Score

ORMP MarketRank™: 

Oramed Pharmaceuticals scored higher than 18% of companies evaluated by MarketBeat, and ranked 890th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.03) to ($0.19) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oramed Pharmaceuticals is -6.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oramed Pharmaceuticals is -6.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oramed Pharmaceuticals has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Oramed Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.20% of the float of Oramed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 0.12%, indicating that investor sentiment is improving.
  • Dividend Yield

    Oramed Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Oramed Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.20% of the float of Oramed Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Oramed Pharmaceuticals has recently decreased by 0.12%, indicating that investor sentiment is improving.
  • News Sentiment

    Oramed Pharmaceuticals has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Oramed Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    9 people have searched for ORMP on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.80% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.

  • Read more about Oramed Pharmaceuticals' insider trading history.
Receive ORMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ORMP Stock News Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.tc pixel
Oramed Pharmaceuticals Inc. (ORMP) - Yahoo Finance
Oramed Pharm Extends Stock Buyback Program
See More Headlines

ORMP Stock Analysis - Frequently Asked Questions

Oramed Pharmaceuticals' stock was trading at $2.42 at the start of the year. Since then, ORMP stock has decreased by 9.1% and is now trading at $2.20.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) released its earnings results on Thursday, August, 14th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.01.

Top institutional shareholders of Oramed Pharmaceuticals include BML Capital Management LLC (7.55%), Bank of America Corp DE (0.35%), Peapod Lane Capital LLC (0.21%) and Connor Clark & Lunn Investment Management Ltd. (0.15%). Insiders that own company stock include Michael Rabinowitz and Nadav Kidron.
View institutional ownership trends
.

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
8/14/2025
Today
8/31/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORMP
CIK
1176309
Employees
10
Year Founded
2006

Profitability

EPS (Trailing Twelve Months)
($0.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.06 million
Net Margins
N/A
Pretax Margin
-1,110.80%
Return on Equity
-19.37%
Return on Assets
-18.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
26.82
Quick Ratio
26.81

Sales & Book Value

Annual Sales
$1.34 million
Price / Sales
67.31
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.75 per share
Price / Book
0.59

Miscellaneous

Outstanding Shares
41,000,000
Free Float
33,705,000
Market Cap
$90.20 million
Optionable
Optionable
Beta
1.60

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:ORMP) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners